Prospect: Information for the User
Wakix 4.5mg Film-Coated Tablets
Wakix 18mg Film-Coated Tablets
pitolisant
This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this prospect carefully before starting to take this medicine, because it contains important information for you.
Wakix contains the active ingredient pitolisant. It is a medication used for the treatment of adult, adolescent, and children over 6 years of age with narcolepsy, with or without cataplexy.
Narcolepsy is a disease that causes excessive daytime sleepiness and a tendency to fall asleep suddenly in inappropriate situations (sleep attacks). Cataplexy usually begins with the sudden onset of muscle weakness or paralysis without loss of consciousness, in response to a sudden emotional reaction such as anger, fear, joy, laughter, or surprise.
The active ingredient, pitolisant, binds to receptors in brain cells involved in the stimulation of the alert state. This helps to combat daytime sleepiness and cataplexy, and to promote wakefulness.
Do not take Wakix:
Warnings and precautions
Consult your doctor before starting to take Wakix if you are in any of the following situations:
If you are in any of these situations, consult your doctor or pharmacist before taking Wakix.
Other aspects to discuss with your doctor or pharmacist:
Some people with a history of psychiatric disorders have reported suicidal thoughts while taking this medication. Inform your doctor immediately if you feel depressed or have suicidal thoughts (see section 4). Ask a close family member or friend to help you detect signs of depression or other changes in your behavior.
Children
Wakix should not be administered to children under 6 years of age.
Use of Wakix with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. Wakix may affect how other medications work and other medications may affect how Wakix works. Your doctor may need to adjust the dose.
Particularly, be cautious if you take Wakix with some antidepressants (such as imipramine, clomipramine, and mirtazapine) and some medications for treating allergic diseases (antihistamines such as, for example, pheniramine maleate, chlorpheniramine, diphenhydramine, promethazine, mepiramine, and doxylamine).
Consult your doctor or pharmacist if you are taking any of the following medications: rifampicin (antibiotic), phenytoin, carbamazepine, and phenobarbital (mainly used to control seizures), quinidine, digoxin (used to treat arrhythmia), paroxetine, fluoxetine, venlafaxine, duloxetine (antidepressants), St. John's Wort (Hypericum perforatum) a plant-based medication for depression, bupropion (antidepressant or substance to help quit smoking), cinacalcet (used to treat parathyroid gland disorders), terbinafine (used to treat fungal infections), metformin, repaglinide (used to treat diabetes), docetaxel, irinotecan (used to treat cancer), cisapride (used to treat gastroesophageal reflux), pimozide (used to treat some mental disorders), halofantrine (used to treat malaria), efavirenz (antiviral to treat HIV), morphine, paracetamol (used as analgesic treatment), dabigatran (used to treat bleeding problems) and warfarin (used to treat heart conditions), probenecid (used to treat gout and gouty arthritis). Pitolisant can be used with modafinil and sodium oxybate.
Wakix may reduce the effectiveness of hormonal contraceptives, so another secure contraceptive method should be used (see section "Pregnancy").
Pregnancy and lactation
If you are pregnant or breastfeeding, or think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Wakix should not be used during pregnancy unless your doctor prescribes it. There is not enough information available to know if there are any specific risks associated with taking Wakix during pregnancy. Women should use contraceptive methods during treatment with Wakix, and at least 21 days after stopping treatment. Since Wakix may reduce the effectiveness of hormonal contraceptives, another secure contraceptive method should be used.
Lactation
In animals, Wakix passes into breast milk. Patients taking Wakix should stop breastfeeding.
Driving and operating machinery
You should be cautious when performing activities that require attention, such as driving cars and operating machinery. If you are unsure if your condition affects your ability to drive, consult your doctor.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Adults
Treatment usually begins with a dose of 9 mg once a day, and is gradually increased over three weeks to reach the most suitable dose. At any time, the doctor may increase or decrease the dose based on the suitability and tolerance to the medication presented by the patient.
It may take several days before the benefits of the medication are perceived, and the maximum benefit is usually observed after several weeks of treatment.
Do not modify the doses of Wakix on your own. Any change in the dosage must be prescribed and supervised by your doctor.
To take a dose of 4.5 mg, take one 4.5 mg tablet.
To take a dose of 9 mg, take two 4.5 mg tablets.
To take a dose of 18 mg, take one 18 mg tablet.
To take a dose of 36 mg, take two 18 mg tablets.
Adolescents and children over 6 years of age
Treatment usually begins with a dose of 4.5 mg once a day and is gradually increased over three weeks to reach the most suitable dose (see above).
If you weigh less than 40 kg, do not take more than 18 mg per day.
Wakix should be taken once a day orally, in the morning during breakfast.
Do not take a dose of Wakix in the afternoon, as the patient may have difficulty sleeping.
If you take more Wakix than you should
If you take too many Wakix tablets, contact the nearest hospital emergency service or consult immediately with your doctor or pharmacist. You may experience headaches, stomach pain, nausea, or irritability. You may also have difficulty sleeping. Carry this leaflet and the rest of the tablets with you.
If you forget to take Wakix
If you forget to take the medication, take the next dose at the usual time, do not take a double dose to compensate for the missed dose.
If you interrupt treatment with Wakix
You must continue taking Wakix for the time prescribed by your doctor. Do not stop taking Wakix suddenly on your own.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them. If you experience any side effects, consult your doctor.
Frequent side effects(may affect up to 1 in 10 people):
Less frequent side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1000 people):
Reporting side effects
If you experience side effects, consult your doctor or pharmacist, even if they do not appear in this prospectus. You can also report them directly through thenational notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
Composition of Wakix
The active ingredient is pitolisant.
Wakix 4.5mg tablets
Each tablet contains pitolisant hydrochloride equivalent to 4.45mg of pitolisant.
Wakix 18mg tablets
Each tablet contains pitolisant hydrochloride equivalent to 17.8mg of pitolisant.
The other components are microcrystalline cellulose, crospovidone type A, talc, magnesium stearate, anhydrous colloidal silica, polyvinyl alcohol, titanium dioxide (E 171), and macrogol 3350.
Appearance of the product and contents of the package
Wakix 4.5mg is presented in film-coated tablets, white, round, biconvex, 3.7mm in diameter, and marked with “5” on one side.
Wakix 18mg is presented in film-coated tablets, white, round, biconvex, 7.5mm in diameter, and marked with “20” on one side.
Wakix is marketed in a bottle of 30 or 90 tablets.
Wakix 4.5 mg:Available in packaging with1bottle of 30 tablets.
Wakix 18 mg:Available in packaging with 1 bottle of 30 tablets or packaging with 1 bottle of 90 tablets or multiple packaging of 90 (3 bottles of 30) tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Bioprojet Pharma
9, rue Rameau
75002 Paris
France
Responsible for manufacturing
Wakix 18 mg
Inpharmasci
ZI N°2 de Prouvy-Rouvignies
1 rue Nungesser
59121 Prouvy
France
Wakix 4.5 mg
Patheon
40 Boulevard de Champaret
38300 Bourgoin-Jallieu
France
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Bioprojet Benelux 0032(0)78050202 | Lietuva UAB Norameda +370 5 2306499 | |
???????? GTS Solution +40 21 528 02 92 | Luxembourg/Luxemburg Bioprojet Benelux 0032(0)78050202 | |
Ceská republika BIOXA Therapeutics (Czech) s.r.o. +420 606 501 778 | Magyarország UAB Norameda +370 5 2306499 | |
Danmark Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 | Malta Bioprojet Pharma 0033 (0)1 47 03 66 33 | |
Deutschland Bioprojet Deutschland GmbH 030/3465 5460-0 | Nederland Bioprojet Benelux N.V. 088 34 34 100 | |
Eesti UAB Norameda Eesti filiaal +372 514 2118 | Norge Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 | |
Ελλ?δα Bioprojet Pharma 0033 (0)1 47 03 66 33 | Österreich AOP Orphan Pharmaceuticals GmbH 0043 1 503 72 44 | |
España Bioprojet Pharma 0033 (0)1 47 03 66 33 | Polska Norameda Polska Sp. z o.o. +48 504 278 778 | |
France Bioprojet Pharma 0033 (0)1 47 03 66 33 | Portugal Ferrer Portugal, S.A 00351 214 449 600 | |
Hrvatska Lenis farmacevtika d.o.o. +386 1 23 50 700 Ireland Bioprojet Pharma 0033 (0)1 47 03 66 33 | România GTS Solution +40 21 528 02 92 Slovenija Lenis farmacevtika d.o.o. +386 1 23 50 700 | |
Ísland Bioprojet Pharma 0033 (0)1 47 03 66 33 | Slovenská republika BIOXA Therapeutics s.r.o. +421 907 927 010 | |
Italia Bioprojet Italia srl +39 02 84254830 | Suomi/Finland Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 | |
Κ?προς Bioprojet Pharma 0033 (0)1 47 03 66 33 | Sverige Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 | |
Latvija Lenis farmacevtika d.o.o. +386 1 23 50 700 | United Kingdom (Northern Ireland) Bioprojet Pharma 0033 (0)1 47 03 66 33 |
Last update of this leaflet:
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency:
http://www.ema.europa.eu.
This leaflet is available in all languages of the European Union/European Economic Area on the website of the European Medicines Agency.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.